David A. Siegel Nu Cana PLC Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.66 - $27.41 $2,244 - $93,194	-3,400 Reduced 22.82%	11,500 $7,000
Q3 2022 Nov 14, 2022	SELL	$0.62 - $26.13 $62 - $2,613	-100 Reduced 0.67%	14,900 $16,000
Q2 2022 Aug 15, 2022	BUY	$0.59 - $1.06 $118 - $212	200 Added 1.35%	15,000 $11,000
Q1 2022 May 16, 2022	BUY	$0.74 - $3.27 $10,952 - $48,396	14,800 New	14,800 $15,000
Q3 2021 Nov 15, 2021	SELL	$1.95 - $2.85 $31,395 - $45,885	-16,100 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.7 - $5.04 $156,330 - $291,816	-57,900 Reduced 78.24%	16,100 $45,000
Q1 2021 May 17, 2021	BUY	$4.38 - $7.0 $221,628 - $354,200	50,600 Added 216.24%	74,000 $369,000
Q4 2020 Feb 16, 2021	BUY	$4.4 - $5.59 $102,960 - $130,806	23,400 New	23,400 $105,000

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $68.4M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.